IL1R1 and non-small cell lung carcinoma: To assess this, an ongoing clinical trial evaluates the use of dupilumab alone versus dupilumab in combination with anakinra (anti-IL-1R) alongside ICI therapy for the treatment of patients with PD-1/PD-L1 refractory metastatic non-small-cell lung cancer (NSCLC), to improve the overall response rate (ORR) (NCT05013450).